Bank of New York Mellon
AVNR

Bank of New York Mellon’s AVANIR PHARMACEUTICALS, INC CL A AVNR Stock Holding History

Bank of New York Mellon’s Portfolio AVNR Stock Details AVNR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-1,038,102
Closed -$17.6M – 4344
2014
Q4 		$17.6M Buy
1,038,102
+7,589
+0.7% +$107K ﹤0.01% 1564
2014
Q3 		$12.3M Buy
1,030,513
+195,910
+23% +$1.34M ﹤0.01% 1767
2014
Q2 		$4.71M Buy
834,603
+8,994
+1% +$41.4K ﹤0.01% 2354
2014
Q1 		$3.03M Buy
825,609
+19,248
+2% +$73.4K ﹤0.01% 2600
2013
Q4 		$2.71M Sell
806,361
-8,716
-1% -$36K ﹤0.01% 2689
2013
Q3 		$3.45M Buy
815,077
+24,433
+3% +$116K ﹤0.01% 2479
2013
Q2 		$3.64M Buy
+790,644
New +$2.72M ﹤0.01% 2383

Bank of New York Mellon's AVNR Position: Q1 2015 in Review

Bank of New York Mellon sold out of AVANIR PHARMACEUTICALS, INC CL A (AVNR) in Q1 2015, closing a stake of 1,038,102 shares — an estimated $17.6M sold.

Bank of New York Mellon first reported a position in AVNR in Q2 2013 and held it in 7 quarters. The position peaked at $17.6M in Q4 2014. 0 funds tracked by Wall St. Rank hold AVNR as of Q1 2015.

  • Bank of New York Mellon reported no remaining AVANIR PHARMACEUTICALS, INC CL A position as of Q1 2015 after selling out during the quarter.
  • Bank of New York Mellon sold 1,038,102 AVANIR PHARMACEUTICALS, INC CL A shares in Q1 2015, an estimated $17.6M.
  • Bank of New York Mellon first reported a position in AVANIR PHARMACEUTICALS, INC CL A in Q2 2013 and held it in 7 quarters.
  • Bank of New York Mellon's AVANIR PHARMACEUTICALS, INC CL A position peaked at $17.6M in Q4 2014.
  • 0 funds tracked by Wall St. Rank held AVANIR PHARMACEUTICALS, INC CL A as of Q1 2015.

Based on Bank of New York Mellon's 13F filing for Q1 2015, filed 13 May 2015.